Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel in Untreated High-risk Mantle Cell Lymphoma
NCT05495464Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acalabrutinib tablet (Variant 1) and brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05495464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495464.